Mar. 14 at 5:46 PM
$ACHL
Reasons to Favor TNXP
1. Broad Pipeline: TNXP has a more diversified portfolio targeting multiple conditions, which reduces reliance on a single therapy.
2. Regulatory Progress: TNXP’s lead candidate (TNX-102 SL) is closer to commercialization, with an FDA PDUFA date set for August 2025.
3. Strategic Partnerships: Strong collaborations with Bilthoven Biologicals and X-Chem, Inc. enhance its research capabilities.
Key Considerations
• Risk: ACHL is riskier due to its narrower focus and recent decision to discontinue key trials, signaling challenges in its pipeline.
• Diversification: TNXP’s broader pipeline and advanced regulatory progress make it a more stable choice.
Conclusion
If you prefer a safer option with near-term catalysts, TNXP may be better. If you’re seeking high-risk, high-reward opportunities in oncology, ACHL could be appealing.
